JGR Capital Partners is an international equity research and investment advisory firm focusing on public companies under $2 billion in market capitalization. We are headquartered in New York City, with affiliate offices in Los Angeles, Shanghai, and São Paulo. Our team of experienced analysts form investment theses based on company and sector expertise, with a strict focus on fundamentals and valuation.
Steven Jon Kaplan began TrueContrarian.com in August 1996 as a weekly blog and later expanded this to a daily newsletter with intraday updates in February 2006. Steve provides financial consulting which emphasizes long-term tax and investment planning. He has been trading his own account, and those of family and close friends, since 1981, and handles separately managed accounts for qualified clients. As a registered investment advisor, Steve charges a 20% performance fee on net profits and zero management fees. He has been quoted in Barron's, Market Watch, Dow Jones Newswires, Seeking Alpha, and Kitco. Steve has appeared on Market Watch cable TV with Stacey Delo and was interviewed by Alisa Parenti on Bloomberg. Since 2010, Danielle Kerani Oberdier has served as Steve's business associate.
Steve enjoys running with the New York Road Runners, composing and performing on piano and voice, writing stories, and traveling to unique places. He enjoys hearing from anyone about a wide range of topics, so please let him know what you think about the web site or whatever is on your mind. You can find his music at http://www.reverbnation.com/stevenjonkaplan .
Self-taught investor who's passionate about building wealth by investing in companies with strong fundamentals who pay exceptional dividends. I'm also an options trader. My blog is Investment Hunting, which can be found at http://www.investmenthunting.com
My blog has one primary goal: Serve as a step-by-step history of what I did to achieve financial independence to be shared with my children and grandchildren. On occasion I share my personal posts with the SA community.
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.
Let me give you some numbers about the US Economy :
Domestic debt at 400% of GDP 70%of the Economy is Consumption based with borrowed money , Now you understand why I am bearish ....I let you imagine the outcome of this debt based casino economy ....join me on my blogs meanwhile :